The UKNSCN patent watch dataset is limited to patent applications published having WO, US, EP and GB designations, along with the granted US, EP and GB patents; hence, in order to place the results of the UK patent watch in a more global context and to give a fuller picture of the worldwide activity in relation to stem cells, an overview of the complete global dataset would be beneficial especially given the recent rise in worldwide patent filings from countries such as China and India.
Executive Summary
The UK National Stem Cell Network (UKNSCN) provided the stem cell community with regular digests of both published and granted patents in the field of stem cells. The patent watch reports were provided by the Intellectual Property Office every two months between 1 November 2008 and 31 October 2011.
In April 2010 a report giving an overview of the first year of stem cell patent digests (1 November 2008 to 31 October 2009 ) was produced by the Patent Informatics Team at the Intellectual Property Office. This report provides an update on this initial patent landscape overview and analyses the patents published and granted during the period from 1 November 2008 to 31 October 2011, with a detailed focus on the current patent landscape and the changes in stem cell patenting over the last two years.
Corporations and academia account for over 85% of both published patent applications and granted stem cell patents, with corporations having a marginally higher market share. Despite the corporate sector having the majority market share, the top applicant of published patent applications is Kyoto University in Japan and the top applicant of granted patents is Wisconsin Alumni Research Foundation in the USA. The University of Edinburgh is the top UK applicant of both published patent applications and granted stem cell patents. Analysis of the patent classifications applied to the published patent applications suggests that recent research is focused on mesenchymal stem cells, pluripotent cells (e.g. embryonic stem cells) and artificially induced pluripotent cells (e.g. iPS). The top three areas for granted stem cells patents are pluripotent cells (e.g. embryonic stem cells), haematopoietic stem cells/uncommitted or multipotent progenitors, and stem cells/progenitor cells/precursor cells of the nervous system.
In the broader fields of neurological and ophthalmic patenting, the corporate sector has the majority of both published patent applications and granted patents. In the antineoplastic area, both the corporate and academic sectors have a similar market share of both published and granted patents. Academia holds the majority market share for published cardiovascular patent applications, but this is reversed for granted cardiovascular patents with corporations having the majority of the market share.
Introduction
The UK National Stem Cell Network (UKNSCN) provided the stem cell community with regular digests of both published and granted patents in the field of stem cells This report provides an update on this initial patent landscape overview and analyses the patents published and granted during the period from 1 November 2008 to 31 October 2011, with a detailed focus on the current patent landscape and the changes in stem cell patenting over the last two years.
In order to provide a macroscopic overview of the dataset provided to the UKNSCN, this report analyses the patent data by considering the following areas:
•

Historical filing profile
•
Invention origin
•
Top applicants
• Breakdown by sector (corporate, academic, government etc)
• Collaboration
•
Breakdown by patent classification
• Breakdown by stem cell technology area
•
Patent landscape map analysis
2 Patent analysis
Dataset summary
The complete UKNSCN patent digests from 1 November 2008 to 31 October 2011 were fused together to provide the dataset used for this report. The UKNSCN patent digests contain details of the search strategy used, but an exemplar search strategy is shown in Appendix A. Table 1 shows a summary of the published patent applications and granted patents in the stem cell dataset.
The dataset is limited to patent applications published having WO, US, EP and GB designations, along with the granted US, EP and GB patents. It should be noted that WO patent applications are those filed using the international Patent Cooperation Treaty (PCT) route; these patent applications lead to national or regional applications at the relevant national offices, hence there will be no granted WO patents.
Published patents Granted patents
Number of patent publications 3134 777
Number of patent families 2499 725 Figure 1 shows the number of published patent applications by earliest priority date. Figure 2 shows a similar chart for the granted stem cell patents, and Figure 3 provides a comparison between the published and granted patents. It is more relevant to look at the priority date instead of the filing (application) date because this gives a better indication as to when the research work relating to the patent applications was being undertaken.
Historical filing profile
A patent is normally published 18 months after the priority date or the filing date (whichever is earlier) 3 , hence the 2010 and 2011 data is incomplete and explains the 'drop-off' in Figure 1 and Figure 2 . 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 Publications Granted Figure 3 : Comparison of published patent applications and granted patents by priority year
Invention origin
Analysis of the priority country gives a good indication of where in the world the research and development is taking place because most applicants will first file for a patent application in the country in which the research work is been undertaken. Given that the dataset is limited to WO, US, EP and GB patent publications, it is not surprising that the US and WO patents dominate these two charts. Figure 6 and Figure 7 show the top applicants for the published patent applications and granted patents within the dataset. It is interesting to note the number of universities and other academic institutions within the top applicants in both charts which is in contrast to the 'corporate domination' usually seen during macroscopic patent analysis of many technology areas; this is most likely due to the fact that stem cells is such a specialised and research-focused area of technology.
Top applicants
Kyoto University in Japan is the top applicant within the published patent data and Wisconsin Alumni Research Foundation in the USA is the top applicant within the granted patent data; these are the same top applicants seen in the original patent landscape report produced in April 2010. It is interesting to compare the similarities between the priority country distributions shown in Figure 4 and Figure 5 and the applicant country distribution shown in Figure 8 . Obviously WO and EP data will appear in Figure 4 and Figure 5 and not Figure 8 , but the ranking and distribution of the 'actual' countries follows a similar trend in both figures as expected. Germany 3%
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However, it is well known that there is a greater propensity to patent in certain countries than others, and the trends shown in Figure 8 may change if the figures are corrected for this difference in behaviour. Therefore, the Relative Specialisation Index (RSI) 4 for each applicant country within the published patent application dataset has been calculated to give an indication of the level of invention in stem cells for each country compared to the overall level of invention in that country, and this is shown in Figure 9. 4 See Appendix B for full details on how the Relative Specialisation Index is calculated
The RSI shown in Figure 9 appears to suggest a very different picture to that shown in Figure 8 . The USA, Japan, Korea and Germany are the top four applicant countries and appear relatively specialised in the field of stem cells, but this is now reversed when the RSI is applied as these countries rank below several others including Singapore, Israel and Australia. These three high-ranking countries, especially Singapore, show much greater levels of patenting in stem cells than expected, despite their modest absolute levels of patenting. Published patents by UK applicants are around the level expected, given the mildly negative value of RSI at -0.11. 
Combined
Sector breakdown
Figure 10 and Figure 11 shows the sector breakdown for all applicants within the published patent applications and granted patents data. In order to provide a breakdown of the types of applicants applying for or holding stem cell related patents, the applicants were categorised as corporate, academic, hospital, government or individuals. For this report the 'academic' category includes universities, research foundations and other institutions. The category 'individuals' was used where no obvious link to an organisation could be found; these patents may legitimately be patents applied for by individual people or the assignment to an organisation may not have yet been have been entered onto the patent databases through statutory-related delays in certain jurisdictions. Figure 10 and Figure 11 show that stem cell patenting is dominated by the corporate and academic sectors, which is perhaps a reflection on the type of research and funding that is required in this area of technology. The higher-than-usual market share from academic applicants is not surprising given the number of universities in the top applicants in Figure 6 and Figure 7 . 
Collaboration
The top filing applicants in both datasets were analysed and the resultant collaborations were plotted on a map. Each of the top applicants is plotted along with any of their collaborators (i.e. not just the top applicants) and each patent is represented by a dot. Figure 14 shows the collaborations between the applicants who have published the most patents and Figure 15 shows the collaborations between those who have the most granted patents. The top filer, Kyoto University, is shown in the top left of Figure 14 and, in addition to a healthy portfolio of patents solely in their own name, they have also collaborated on patents with other Japanese universities (e.g. Gifu University and Tohofu University), Japanese institutions (e.g. Stem Cell and Drug Discovery Institution in Kyoto) and both Japanese and international corporations (e.g. Oriental Yeast in Japan, and iPierian, who are based in San Francisco, USA).
The other major collaboration 'web' in the top right of Figure 14 revolves around Central Hospital Corporation who do business as Massachusetts General Hospital (MGH).
MGH is the third-oldest and one of the biggest hospitals in the USA 5 and serves as the major non-profit teaching hospital of Harvard College; this explains the close links and collaboration between these two organisations. MGH have no international collaborators but have collaborated domestically in the USA with Massachusetts Institute of Technology (MIT), the University of North Carolina, the Children's Medical Center of Dallas, the Immune Disease Institute and the Dana-Farber Cancer Institute (both based in Boston), and Maryland biotechnology company Viacell.
The top UK applicant, the University of Edinburgh, has collaborated on one published patent application (US 2010/086999 A1, published 8 April 2010), entitled "Differentiation of primate pluripotent cells to hepatocytelineage cells", with Geron Corporation (a biotechnology company based in California, USA). Figure 14 shows that all but one of the top applicants shown in Figure 6 have had at least one published patent application with at least one collaborator, whereas Figure 15 shows that five of the top applicants shown in Figure 7 have no collaborators (the five isolated 'blobs' located near the bottom left of the map). Figure 16 to Figure 21 show a series of charts highlighting the top ECLA (European patent classification 6 ) and IPC (International Patent Classification 7 ) applied to the published patent applications and granted patents in the dataset.
Analysis by patent classification
Given that the focus of the UKNSCN patent watch service is to identify relevant stem cell patents, it is not surprising to see the top technology areas, as defined by the top ECLA sub-groups, being stem cell related. The top three subgroups for published patent applications, as shown in Figure  16 are mesenchymal stem cells (C12N5/06B21P), pluripotent cells e.g. embryonic stem cells (C12N5/06B2P) and artificially induced pluripotent cells e.g. iPS (C12N5/06B3A).
For granted patents, the top three subgroups, as shown in Figure 17 , are pluripotent cells e.g. embryonic stem cells (C12N5/06B2P), haematopoietic stem cells/uncommitted or multipotent progenitors (C12N5/06B11P), and stem cells/progenitor cells/ precursor cells of the nervous system (C12N5/06B8P).
Given the timescales involved in granting patents, it follows that the ECLA and IPC sub-groups applied to the published patent applications give an indication of where more recent activity is taking place. 
Analysis by stem cell technology area
The datasets were also sub-divided into four subsets relating to four different areas of interest using specific IPC sub-groups in the heading A61P. These subsets were chosen for the first patent landscape report in April 2010 because they encompassed the most clinically relevant applications and uses of stem cells; the same four areas are used in this report for comparison. Figure 22 to Figure 25 show how the four data subsets were analysed by sector and compared between the two date ranges used previously, and Figure 26 and Figure 27 show the distribution of each technology area by sector. A dataset combining all UKNSCN published patent applications and granted patents was used to produce the patent landscape shown in Figure 28 . The two "snowcapped peaks" in the centre of the map shows that the highest concentration of patents in this dataset relate to patents comprising keywords such as "pluripotent" and "mesenchymal", which is consistent with the top ECLA subgroups discussed previously in section 2.7.
8 Further details regarding how patent landscape maps are produced is given in Appendix C.
The patent landscape map shown in Figure 29 is the same patent map shown in Figure 28 , but with specific patents (dots) highlighted. The map in Figure 29 highlights the granted stem cell patents and shows a fairly even spread across the whole stem cell patent landscape. Figure 30 to Figure 33 highlight the patents relating to the four stem cell technology areas discussed previously, with Figure  34 showing them all on one map and Figure 35 showing a rough approximation for the regions where patents relating to each of these four technology areas can be found. Figure 36 shows the location of published and granted patents from UK applicants and there appears to be no single area of stem cell specialism for UK applicants. Corporations and academia account for over 85% of both published patent applications and granted stem cell patents, with corporations having a marginally higher market share. Despite the corporate sector having the majority market share, it is interesting to note that the top applicant of published patent applications is Kyoto University in Japan and the top applicant of granted patents is Wisconsin Alumni Research Foundation in the USA. The University of Edinburgh is the top UK applicant of both published patent applications and granted stem cell patents.
Due to lengthy patent pendency times, the more recent areas of research and new entrants into this area of technology will be reflected in the published patent applications rather than the granted patents. Analysis of the ECLA and IPC classifications applied to the published patent applications suggests that recent research is focussed on mesenchymal stem cells, pluripotent cells (e.g. embryonic stem cells) and artificially induced pluripotent cells (e.g. iPS). In general, the classification areas of granted patents suggest areas of research that were studied several years previously; the top three areas for granted stem cells patents are pluripotent cells (e.g. embryonic stem cells), haematopoietic stem cells/uncommitted or multipotent progenitors, and stem cells/progenitor cells/precursor cells of the nervous system. This suggests that embryonic stem cell research has been going on for many years now and is still on-going.
In the broader fields of neurological and ophthalmic patenting, the corporate sector has the majority of both published patent applications and granted patents. In antineoplastic areas, both the corporate and academic sectors have a similar market share of both published and granted patents. Academia holds the majority market share (43%) for published cardiovascular patent applications, but this is reversed for granted cardiovascular patents with corporations having over 60% of the market share. In all four technology areas studied, it is interesting to note how the market share of the hospital sector increases between published patent applications and granted patents (e.g. in the antineoplastic area, the hospital sector holds only 5% of all published patent applications, but yet it holds 20% of all granted patents); this could be because research is hospitals is very innovative and at the cutting-edge of stem cell research and so the ratio of granted patents to published patent applications for the hospital sector is higher than the other sectors.
The UKNSCN dataset is limited to patent applications published having WO, US, EP and GB designations, along with the granted US, EP and GB patents; hence, in order to place the results of the UK patent watch in a more global context and to give a fuller picture of the worldwide activity in relation to stem cells, an overview of the complete global dataset would be beneficial especially given the recent rise in worldwide patent filings from countries such as China and India.
